
    
      Patients are randomized to 1 of 2 groups for 48 weeks of open-label treatment. Group 1
      receives ddI EC plus d4T plus NFV. Group 2 receives Combivir plus NFV. Antiviral activity is
      determined by the proportion of patients with HIV RNA levels of less than 400 copies/ml at
      Week 48.
    
  